PTC Therapeutics, Inc. (PTCT) stock
PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3031% above fair value
$63.49+0.13 (+0.21%)
Close on Nov 13, 2026Market cap $5.30BP/E –Yield –
PTC Therapeutics total assets
Total assets on the balance sheet at the end of each period.
PTC Therapeutics's total assets was $3.21B at Sep 30, 2026. For fiscal 2025 it was $2.90B, up 70.0% from the year before. Over ten years it grew 23.0% a year on average. The highest annual figure on record is $2.90B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.90B | +70.0% |
| FY2024 | Dec 31, 2024 | $1.71B | -10.1% |
| FY2023 | Dec 31, 2023 | $1.90B | +11.1% |
| FY2022 | Dec 31, 2022 | $1.71B | -12.0% |
| FY2021 | Dec 31, 2021 | $1.94B | -12.2% |
| FY2020 | Dec 31, 2020 | $2.21B | +36.0% |
| FY2019 | Dec 31, 2019 | $1.62B | +45.1% |
| FY2018 | Dec 31, 2018 | $1.12B | +185.8% |
| FY2017 | Dec 31, 2017 | $391.65M | +45.4% |
| FY2016 | Dec 31, 2016 | $269.35M | -26.3% |
| FY2015 | Dec 31, 2015 | $365.28M | +9.6% |
| FY2014 | Dec 31, 2014 | $333.22M | +119.4% |
| FY2013 | Dec 31, 2013 | $151.90M | +1062.0% |
| FY2012 | Dec 31, 2012 | $13.07M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.21B | +21.3% |
| Q2 FY2026 | Jun 30, 2026 | $3.25B | +23.4% |
| Q1 FY2026 | Mar 31, 2026 | $2.87B | +8.0% |
| Q4 FY2025 | Dec 31, 2025 | $2.90B | +70.0% |
| Q3 FY2025 | Sep 30, 2025 | $2.64B | +43.5% |
| Q2 FY2025 | Jun 30, 2025 | $2.63B | +37.5% |
| Q1 FY2025 | Mar 31, 2025 | $2.66B | +48.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.71B | -10.1% |
| Q3 FY2024 | Sep 30, 2024 | $1.84B | +46.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.92B | +43.2% |
| Q1 FY2024 | Mar 31, 2024 | $1.79B | +11.2% |
| Q4 FY2023 | Dec 31, 2023 | $1.90B | +11.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.26B | -20.1% |
| Q2 FY2023 | Jun 30, 2023 | $1.34B | -25.8% |
| Q1 FY2023 | Mar 31, 2023 | $1.61B | -10.6% |
| Q4 FY2022 | Dec 31, 2022 | $1.71B | -12.0% |
| Q3 FY2022 | Sep 30, 2022 | $1.58B | -21.5% |
| Q2 FY2022 | Jun 30, 2022 | $1.80B | -12.4% |
| Q1 FY2022 | Mar 31, 2022 | $1.80B | -14.8% |
| Q4 FY2021 | Dec 31, 2021 | $1.94B | -12.2% |
| Q3 FY2021 | Sep 30, 2021 | $2.01B | -8.0% |
| Q2 FY2021 | Jun 30, 2021 | $2.06B | +39.4% |
| Q1 FY2021 | Mar 31, 2021 | $2.11B | +36.6% |
| Q4 FY2020 | Dec 31, 2020 | $2.21B | +36.0% |
| Q3 FY2020 | Sep 30, 2020 | $2.18B | +32.9% |
| Q2 FY2020 | Jun 30, 2020 | $1.48B | +14.3% |
| Q1 FY2020 | Mar 31, 2020 | $1.55B | +20.4% |
| Q4 FY2019 | Dec 31, 2019 | $1.62B | +45.1% |
| Q3 FY2019 | Sep 30, 2019 | $1.64B | +59.6% |
| Q2 FY2019 | Jun 30, 2019 | $1.29B | +152.4% |
| Q1 FY2019 | Mar 31, 2019 | $1.28B | +238.4% |
| Q4 FY2018 | Dec 31, 2018 | $1.12B | +185.8% |
| Q3 FY2018 | Sep 30, 2018 | $1.03B | +179.7% |
| Q2 FY2018 | Jun 30, 2018 | $511.77M | +33.6% |
| Q1 FY2018 | Mar 31, 2018 | $379.41M | +52.6% |
| Q4 FY2017 | Dec 31, 2017 | $391.65M | +45.4% |
| Q3 FY2017 | Sep 30, 2017 | $367.72M | – |
| Q2 FY2017 | Jun 30, 2017 | $383.08M | – |
| Q1 FY2017 | Mar 31, 2017 | $248.65M | – |
| Q4 FY2016 | Dec 31, 2016 | $269.35M | – |
See a number that looks wrong?